纳米蛋白结合型紫杉醇联合顺铂治疗食管鳞状细胞癌的疗效分析

Efficacy of nano-albumin bound paclitaxel combined with cisplatin in treatment of esophageal squamous cell carcinoma

目的探究纳米蛋白结合型紫杉醇联合顺铂治疗食管鳞状细胞癌的疗效和安全性。方法选择2019年1月~2020年12月于江苏省泰州市第二人民医院就诊的110例复发转移性食管鳞癌患者作为研究对象,采用纳米蛋白结合型紫杉醇联合顺铂治疗,具体用药为:纳米蛋白结合型紫杉醇260 mg/m^(2),第1天,静脉滴注30 min以上,顺铂75 mg/m^(2),第1天,静脉滴注2 h;每21 d作为一个周期。采用实体瘤疗效评价标准评估临床疗效,美国国立癌症研究所通用毒性标准5.0评估患者的不良反应。对所有患者进行随访,直至患者失访或死亡,分析患者的生存情况。结果2例患者中途退出研究,研究最终包括108例研究对象。无病例达到完全缓解,部分缓解患者65(60.19%)例,疾病稳定者30(27.78%)例,疾病进展13(12.04%)例,客观缓解率60.19%,疾病控制率87.96%。患者的中位无进展生存期为5.8(4.7~7.2)个月,见图1;中位总生存期为16.3(12.5~18.6)个月。无患者出现4级不良反应,不良反应主要包括中性粒细胞减少、白细胞减少、贫血、恶心、呕吐以及腹泻。结论纳米蛋白结合型紫杉醇联合顺铂治疗食管鳞状细胞癌临床效果良好,安全性良好。

Objective To assess the efficacy and safety of nano-albumin bound paclitaxel combined with cisplatin in the treatment of esophageal squamous cell carcinoma.Methods A total of 110 patients with recurrent and metastatic esophageal squamous cell carcinoma who were treated at Jiangsu Taizhou Second People's Hospital from January 2019 to December 2020 were selected as the subjects.All patients received nano-albumin bound paclitaxel combined with cisplatin treatment as follows:nano-albumin bound paclitaxel 260 mg/m^(2)administered intravenously(IV)for more than 30 minutes on day 1,cisplatin 75 mg/m^(2)administered IV for 2 hours on day 1 of a 21-day cycle for up to 8 cycles.The Response Evaluation Criteria in Solid Tumors were used to evaluate the clinical efficacy,and the National Cancer Institute Common Toxicity Criteria 5.0 were used to evaluate the adverse reactions.All patients were followed until loss to follow-up or death,and the survival of the patients was analyzed.Results Two patients withdrew from the study halfway,and 108 subjects were finally included for analysis.No patients achieved complete response,65(60.19%)achieved partial response,30(27.78%)had stable disease,and 13(12.04%)had progressive disease;the objective response rate was 60.19%and the disease control rate was 87.96%.The patient's median progression-free survival was 5.8(4.7~7.2)months.The median overall survival was 16.3(12.5~18.6)months.No patients developed grade 4 adverse reactions.The adverse reactions mainly included neutropenia,leukopenia,anemia,nausea,vomiting,and diarrhea.Conclusion The combination of nano-albumin bound paclitaxel and cisplatin in the treatment of esophageal squamous cell carcinoma has good efficacy and safety.